| Home | E-Submission | Sitemap | Editorial Office |  
Korean J Urol Oncol > Volume 13(3); 2015 > Article
The Korean Journal of Urological Oncology 2015;13(3): 115-121.
전립선비대증을 동반한 발기부전 환자에서 Mirodenafil 50mg 매일 복용요법과 100mg 필요 시 복용요법의 유효성 비교: 다기관, 무작위 대조 연구
조중훈1, 서준상1, 김규식1, 김태효2, 노준화3, 배재현4, 오철영5, 이승환6, 조성용7, 최재덕8, 한준현5, 이승욱1
1한양대학교 의과대학 비뇨기과학교실, 2동아대학교 의과대학 비뇨기과학교실, 3광주기독병원 비뇨기과학교실, 4고려대학교 의과대학 비뇨기과학교실, 5한림대학교 의과대학 비뇨기과학교실, 6연세대학교 의과대학 비뇨기과학교실, 7서울대학교 의과대학 비뇨기과학교실, 8한일병원 비뇨기과학교실
Comparison of Erectile Dysfunction Treatment Efficacy of Mirodenalfil 50mg Once Daily and 100mg On-Demand in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction: Multicenter, Randomized
Jung Hoon Cho 1, Jun Sang Seo 1, Kyu Shik Kim 1, Tae Hyo Kim 2, Joon Hwa Noh 3, Jae Hyun Bae 4, Cheol Young Oh 5, Seung Hwan Lee 6, Sung Yong Cho 7, Jae Duck Choi 8, Jun Hyun Han 5, Seung Wook Lee 1
1Department of Urology, Hanyang University College of Medicine, Seoul, 2Department of Urology, Dong-A University College of Medicine, Busan, 3Department of Urology, Kwangju Christian Hospital, Gwangju, 4Department of Urology, Korea University College of Medicine, 5Department of Urology, Hanlim University College of Medicine, 6Department of Urology,Yonsei University College of Medicine, 7Department of Urology, Seoul National University College of Medicine, 8Department of Urology, KEPCO Medical Center, Seoul, Korea
Published online: December 30, 2015.
To Compare the improvement of erectile dysfunction(ED) and lower urinary tract symptoms(LUTS) as well as the efficacy of mirodenalfil 50mg once daily and 100mg on-demand in patients with benign prostatic hyperplasia(BPH) and erectile dysfunction(ED).
Materials and Methods:
Prospective study was done with 220 patients who had BPH and ED from June 2013 to October 2014. Out of 220 individuals, 260 met inclusion criteria and 204 finished the research. Patients were divided into two groups. Group 1 had mirodenafil 50mg once daily and Group 2 had mirodenafil 100mg on-demand. The five-item version of the International Index of Erectile Function(IIEF-5), International Prostate Symptom Score(IPSS), Qmax, and residual urine volume(PVR) were assessed immediately before initiation of treatment(V1) and after four(V2) and twelve weeks of treatment(V3).
No difference of IIEF-5, IPSS, Qmax, and PVR between two groups in V1. At V3, both groups had improvements of IPSS and group 1 had better improvements(-5.1±4.4 vs. -3.1±3.9 p<0.001). And Group 1 had larger improvements than Group 2 in Qmax significantly. No difference in PVR in both groups comparing V1 vs. V2 and V1 vs V3. Group 1 had better improved IIEF-5 than Group 2(V1 vs. V3 : 4.8±5.8 vs. 4.4±5.1; p=0.032). There was no drop out patients due to cardiovascular problems.
Once daily mirodenafil 50mg was more efficacious in treating both ED and LUTS than on-demand dosing mirodenafil 100mg without any complication of cardiovascular problems. (Korean J Urol Oncol 2015;13:115-121)
Key Words: Mirodenafil; Lower urinary tract symptoms; Erectile dysfunction; Benign prostatic hyperplasia
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
Related article
Editorial Office
Department of Urology, Chung-Ang University Hospital
102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-1819   Fax: +82-2-6294-1406   E-mail: journal@kjuo.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Urological Oncology Society and The Korean Prostate Society.                 Developed in M2PI
Close layer
prev next